← Back

Founder Securities Co Ltd

Founder Securities Co., Ltd. engages in the securities business in the People's Republic of China. The company offers wealth management services, including securities brokerage, institutional business, credit business, distribution of financial products, futures brokerage, and other businesses. It also provides investment banking services, such as equity and bond financing, mergers and acquisitions, recommendation and listing, and financial consultancy and other services. In addition, the company offers asset management services comprising securities assets and public fund management, private equity investment management, futures asset management, and other businesses. Further, it offers investment and trading services; and research and consulting services for institutional clients. Founder Securities Co., Ltd. was incorporated in 1988 and is headquartered in Changsha, the People's Republic of China.

Price · split & dividend adjusted
News & notes moving 601901.CG
601901.CG

Founder Securities appoints Li Yan as board secretary

Founder Securities Co., Ltd. announced on August 17, 2026 that, following approval at the first meeting of the sixth board of directors, Li Yan has been appointed as board secretary. Li Yan also serves as a director, member of the executive committee, vice president, and chief financial officer of the company. He previously held positions including assistant to the general manager, director, and chief financial officer at financial enterprises such as Ping An Insurance Group, Ping An Life, Ping An Securities, and Ping An Wealth Management, with more than ten years of experience in finance and accounting. The announcement shows that Li Yan completed pre-appointment training for board secretaries at the Shanghai Stock Exchange in 2023 and obtained certification, completed follow-up training in 2026, and the company has completed the registration of his appointment as board secretary with the Shanghai Stock Exchange. He does not directly oversee business matters, and the company will facilitate his compliance with relevant requirements during the regulatory transition period. There are no circumstances that would prevent him from serving as a director, senior executive, or board secretary of a listed company.
Jiemian·9dRead more ▾
Biotech & Genomic Medicineimpact 4

2026 National Essential Medicines List officially released, innovative drugs included in batches

The 2026 National Essential Medicines List has been officially released. The number of proprietary Chinese medicines has expanded significantly to 318 varieties, with 65 newly added varieties achieving combined terminal sales of over 16 billion yuan at public medical institutions in 2025. For the first time, the new essential medicines list includes 16 clinically high-value innovative drugs in a batch, among which are four domestically developed Class I original new drugs. This marks a step forward for innovative drugs from medical insurance access to hospital deployment and grassroots availability. China Post Securities believes that the 986 deployment principle is expected to drive rapid volume growth for listed varieties, particularly benefiting traditional Chinese medicine enterprises that have already established channel advantages in grassroots markets. At the same time, innovative drug companies such as RemeGen, whose products have entered the basic medication list, are poised to open up broad space for long-term standardized treatment. Founder Securities pointed out that this round of adjustments has strengthened the investment themes of policy implementation, channel volume growth, and financial report penetration.
Jiemian·44dRead more ▾